Browse
related articles
DuBiotech partners global research leader to develop regulatory framework
- United Arab Emirates: Saturday, February 04 - 2006 at 15:08
- PRESS RELEASE
The Dubai Biotechnology and Research Park (DuBiotech) announced today that it has embarked on developing comprehensive scientific and regulatory standards for biotechnology activity in the park with expertise from RTI International, one of the world's largest independent non-profit research organisations.
"Biotechnology opens a whole new world of economic and social possibility for the region," said Dr. Abdulqader Al Khayat, Executive Director of DuBiotech.
"A sound regulatory framework is necessary to harness biotechnology's potential to improve health, enhance quality of life, support the environment and promote a sustainable economy. The regulations will provide a secure and encouraging environment for research and innovation, which is central to the growth of biotechnology," he added.
"We are keen to develop a regulatory framework based on international best practices for the park, and that is why we chose RTI International as a consultant for the project. "RTI's mission, reputation and commitment to research integrity are exactly what we were looking for in this project," Dr. Al Khayat further said.
"We're excited to be helping an organization like DuBiotech set the stage for world-class research and development," said Adam Saffer, Ph.D., Executive Vice President of Strategic Planning at RTI. "As the founding tenant of Research Triangle Park, we're looking forward to the opportunity to share our knowledge and expertise to help establish DuBiotech as one of the leading research and development zones in the Middle East."
A world leader in environment, health, and international development research and services, RTI International has nearly 50 years of experience and has completed projects in more than 120 countries. It is recognized around the world for its research excellence in the fields of health, toxicology, laboratory sciences and environmental research.
As a leading research and technical services provider for the U.S. Environmental Protection Agency, Food and Drug Administration, Health and Human Services, National Institutes of Health and numerous other government agencies, RTI has extensive experience supporting national programmes in environment and health for both government and industry.
Also consider reading:
Browse
related articles
Notes and media contacts
About DuBiotechAnnounced in February 2005, the Dubai Biotechnology and Research Park (DuBiotech) is a science and business park dedicated to the biotech industry, set within a free zone infrastructure. DuBiotech has two main areas of interest. The first is the Foundation for Research and Innovation (FRI) which will be the main arm focusing on government funded R&D. The FRI will initially focus on medical research and genetics, plant biotechnology encompassing food and agricultural biotech, environmental biotech and equine-related biotechnology. Other areas include drug discovery, stem cell research, infectious diseases and forensic research. The second arm of DuBiotech aims to set up a biotechnology industry cluster with the appropriate infrastructure, facilities and service for incubators, R&D labs, biotech-related educational institutions, suppliers, biotech-related manufacturing companies and organizations from other sectors in the industry. DuBiotech is advised by an independent steering committee on scientific, business and ethical matters.
About RTI International
RTI International is an independent nonprofit research organization dedicated to conducting research and development that improves the human condition. With a staff of more than 2,500 people, RTI International offers innovative research and technical solutions to governments and businesses worldwide in the areas of health and pharmaceuticals, advanced technology, surveys and statistics, education and training, economic and social development, and the environment. For more information, please visit: www.rti.org.
Disclaimer:
Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com
Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.
For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions
Posted by Lara Lynn Golden, News Editor
